Haemophilia A News and Research

RSS
Hemophilia A is an X-linked, recessive, bleeding disorder caused by a deficiency in the activity of coagulation factor VIII. Affected individuals develop a variable phenotype of hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds. The disorder is caused by heterogeneous mutations in the factor VIII gene which maps to Xq28.
Non-Invasive prenatal blood test to detect chromosomal abnormalities in foetus

Non-Invasive prenatal blood test to detect chromosomal abnormalities in foetus

Ban on Gay men from donating blood to be reviewed in light of new evidence

Ban on Gay men from donating blood to be reviewed in light of new evidence

Study may pave for effective treatments for blood clotting disorders

Study may pave for effective treatments for blood clotting disorders

Lysteda tablets to treat menorrhagia approved by the FDA

Lysteda tablets to treat menorrhagia approved by the FDA

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Lack of hemophilia treatment in the developing world costing lives

Lack of hemophilia treatment in the developing world costing lives

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

Gene therapy saves two children with adrenoleukodystrophy

Gene therapy saves two children with adrenoleukodystrophy

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

Novo Nordisk re-launches its changing possibilities in hemophilia campaign

Novo Nordisk re-launches its changing possibilities in hemophilia campaign

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

New York Governor participates in roundtable discussion on stem cell research

New York Governor participates in roundtable discussion on stem cell research

Amorfix Life Sciences to present Amorfix's EP-vCJD blood screening test for vCJD at WFH Global Forum

Amorfix Life Sciences to present Amorfix's EP-vCJD blood screening test for vCJD at WFH Global Forum

CSL Behring offers new dosage strength of Helixate FS in U.S.

CSL Behring offers new dosage strength of Helixate FS in U.S.

Inhibitor Education Summits to address pertinent topics regarding hemophilia

Inhibitor Education Summits to address pertinent topics regarding hemophilia

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels